Historical overview of the role of platelets in hemostasis and thrombosis

Haematologica

Volumn 86, Issue 4, 2001, Pages 349-356

  De Gaetano, G ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

Hemostasis; History; Platelets; Thrombosis

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; ACETYLSALICYLIC ACID; ADENOSINE DERIVATIVE; ADENOSINE DIPHOSPHATE; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHELATING AGENT; CARBACYCLIN; CLOFIBRATE; COLCHICINE; DAZOXIBEN; DIPYRIDAMOLE; ENZYME INHIBITOR; GINKGOLIDE B; GLUCOSAMINE; HEPARIN; ILOPROST; IMIDAZOLE; KADSURENONE; KETANSERIN; N,N' BIS[7 (3 CHLOROANILINOSULFONYL) 1,2,3,4 TETRAHYDRO 1 ISOQUINOLYL]DISULFONYLIMIDE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN D2; SULFINPYRAZONE; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; UNINDEXED DRUG;

BLOOD CLOTTING; BLOOD CLOTTING TIME; CANCER GROWTH; CELL INTERACTION; DRUG MECHANISM; DRUG METABOLISM; GRAFT REJECTION; HEMOSTASIS; HISTORY OF MEDICINE; INFLAMMATION; LEUKOCYTE; METASTASIS; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS;

BLOOD PLATELETS; HEMATOLOGY; HEMOSTASIS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0035013731     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Über einen neuen formbestandteil des biutes und dessen rolle bei der thrombose und blutgerinnung
2. Untersuchungen über thrombose, bildung der thromben
3. The blood platelet: Its clinical significance
4. Contribution ȧ l'étude de la physiologic normale et pathologique du globulin (plaquettes de Bizzozero)
5. Studies on the enigma of the hemostatic dysfunction of hemophilia
6. L'hémostase spontanée. Etude synthetique et analytique
7. Thrombostenin, a contractile protein from blood platelets
8. Hypothesis for the aggregation of platelets by nucleotides
9. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets
10. RoLe of adenosine diphosphate in the aggregation of human blood platelets by thrombin and by fatty acids
11. The blood piatelet release reaction
12. The aggregation of blood platelets
13. Platelet aggregation. PART II. Some results from a new method of study
14. ADP receptors and clinical bleeding disorders
15. Influence de l'acide acetyl salicylique dans les maladies hémorrhagiques
16. Allongement du temps de saignement sons l'influence de certain médicaments
17. Salicylates and bleeding: The aspirin tolerance test
18. Impaired platelet-connective tissue reaction in man after aspirin ingestion
19. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion
20. Effect of salicylates on human platelets
21. The effect of acetylsalicylic acid on platelet function
22. A simple method to study the "stabilising" effect of chemicals and drugs on the platelet membrane
23. Thromboembolism
24. Discussion
25. Anti-inflammatory drugs and the prevention of thrombosis
26. Secondary prevention of vascular disease by prolonged antiplatelet treatment
27. Factors influencing platelet function: Adhesion, release, and aggregation
28. Aspirin selectively inhibits prostaglandin production in human platelets
29. Indomethacin and aspirin abolish prostaglandin release from the spleen
30. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
31. Pharmacology of antiplatelet drugs
32. An enzyme isolated from arteries transforms prostaglandin endoper-oxides to an unstable substance that inhibits platelet aggregation
33. Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin 12-like activity
34. Aspirin: A paradoxical effect on bleeding-time
35. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin
36. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin
37. The inhibitory effect of aspirin on platelet and vascular prostaglandins in rats cannot be completely dissociated
38. Differential inhibition of prostacyclin production and platelet aggregation by aspirin
39. "Aspirinated" platelets are hemostatic in thrombocytopenic rats with "non-aspirinated" vessel walls-evidence from an exchange transfusion model
40. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
41. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyelin and platelet thromboxane production in patients with atheroselerosis
42. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction
43. Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin
44. Monitoring the entry of new platelets into the circulation after ingestion of aspirin
45. Proceedings of the workshop on platelet-active drugs in the secondary prevention of cardiovascular events
46. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study
47. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial
48. Pharmacology of platelet inhibition in humans: Implications of the salicylate-aspirin interaction
49. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin
50. Aspirin kinetics and platelet aggregation in man
51. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase
52. Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood
53. Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels
54. Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyelooxygenase activity is reduced by portacaval shunt in rats
55. Low dose aspirin does not prevent fibrinolytic response to venous occlusion
56. The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue
57. Prostacyclin is required for t-PA release after venous occlusion
58. Round-the-Table Conference on normal and modified platelet aggregation
59. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia
60. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
61. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
62. Platelet activation by polymorphonuclear leukocytes: Role of cathepsin G and P-selectin
63. P-selectin-beta 2-integrin cross-talk: A molecular mechanism for polymorphonudear leukocyte recruitment at the site of vascular damage